Maravai LifeSciences Holdings, Inc.

NasdaqGS:MRVI Stock Report

Market Cap: US$1.2b

Maravai LifeSciences Holdings Valuation

Is MRVI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MRVI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$8.01
Fair Value
38.4% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: MRVI ($4.93) is trading below our estimate of fair value ($8.01)

Significantly Below Fair Value: MRVI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MRVI?

Key metric: As MRVI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MRVI. This is calculated by dividing MRVI's market cap by their current revenue.
What is MRVI's PS Ratio?
PS Ratio2.5x
SalesUS$276.92m
Market CapUS$1.24b

Price to Sales Ratio vs Peers

How does MRVI's PS Ratio compare to its peers?

The above table shows the PS ratio for MRVI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11x
BLFS BioLife Solutions
8.6x13.5%US$1.3b
FTRE Fortrea Holdings
0.5x3.4%US$1.5b
ABCL AbCellera Biologics
28.4x15.8%US$936.3m
ADPT Adaptive Biotechnologies
6.5x17.9%US$1.1b
MRVI Maravai LifeSciences Holdings
2.5x8.1%US$1.2b

Price-To-Sales vs Peers: MRVI is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (11x).

Price to Sales Ratio vs Industry

How does MRVI's PS Ratio compare vs other companies in the US Life Sciences Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.5x3.4%US$1.51b
ATLN Atlantic International
0.6xn/aUS$248.27m
NOTV Inotiv
0.3x6.0%US$144.31m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
MRVI 2.5xIndustry Avg. 3.4xNo. of Companies9PS02.85.68.411.214+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MRVI is good value based on its Price-To-Sales Ratio (2.5x) compared to the US Life Sciences industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is MRVI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MRVI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ratio3x

Price-To-Sales vs Fair Ratio: MRVI is good value based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MRVI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.93
US$9.33
+89.2%
24.0%US$13.20US$4.25n/a12
Jan ’26US$5.45
US$9.07
+66.5%
25.6%US$13.20US$4.25n/a13
Dec ’25US$5.67
US$9.73
+71.5%
20.7%US$13.20US$7.00n/a12
Nov ’25US$7.46
US$11.18
+49.9%
22.9%US$17.00US$7.00n/a12
Oct ’25US$8.05
US$11.27
+40.0%
21.6%US$17.00US$8.00n/a12
Sep ’25US$9.05
US$11.10
+22.7%
18.7%US$15.00US$8.00n/a12
Aug ’25US$9.63
US$10.75
+11.6%
22.3%US$15.00US$7.00n/a10
Jul ’25US$6.94
US$10.69
+54.1%
20.7%US$15.00US$8.00n/a11
Jun ’25US$8.67
US$10.42
+20.2%
22.4%US$15.00US$8.00n/a11
May ’25US$8.42
US$9.78
+16.2%
28.7%US$15.00US$6.50n/a11
Apr ’25US$8.60
US$9.16
+6.5%
23.4%US$14.00US$6.50n/a10
Mar ’25US$7.59
US$9.16
+20.7%
23.4%US$14.00US$6.50n/a10
Feb ’25US$5.38
US$8.91
+65.7%
21.6%US$12.00US$6.00US$4.9310
Jan ’25US$6.55
US$9.80
+49.6%
34.1%US$18.00US$6.00US$5.4510
Dec ’24US$5.37
US$10.00
+86.2%
32.9%US$18.00US$6.00US$5.6710
Nov ’24US$6.71
US$13.50
+101.2%
23.0%US$18.00US$8.00US$7.4610
Oct ’24US$10.00
US$13.50
+35.0%
23.0%US$18.00US$8.00US$8.0510
Sep ’24US$10.30
US$13.34
+29.5%
22.7%US$18.00US$8.00US$9.0511
Aug ’24US$11.03
US$18.58
+68.5%
23.5%US$27.00US$12.00US$9.6312
Jul ’24US$12.43
US$18.82
+51.4%
23.1%US$27.00US$13.00US$6.9411
Jun ’24US$13.17
US$18.82
+42.9%
23.1%US$27.00US$13.00US$8.6711
May ’24US$13.63
US$21.18
+55.4%
20.6%US$29.00US$15.00US$8.4211
Apr ’24US$14.01
US$21.27
+51.8%
20.0%US$29.00US$15.00US$8.6011
Mar ’24US$14.97
US$21.27
+42.1%
20.0%US$29.00US$15.00US$7.5911
Feb ’24US$15.14
US$23.18
+53.1%
22.2%US$32.00US$16.00US$5.3811
Analyst Price Target
Consensus Narrative from 12 Analysts
US$9.33
Fair Value
47.2% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 08:51
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Maravai LifeSciences Holdings, Inc. is covered by 17 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Michael RyskinBofA Global Research
Matthew HewittCraig-Hallum Capital Group LLC